Presentation is loading. Please wait.

Presentation is loading. Please wait.

P2.33: Safety Profile of Nivolumab Administered as 30-Minute (MIN) Infusion: Analysis of Data From Checkmate 153  David Waterhouse, Leora Horn, Craig.

Published byAnthony Mills Modified over 5 years ago

Similar presentations

Presentation on theme: "P2.33: Safety Profile of Nivolumab Administered as 30-Minute (MIN) Infusion: Analysis of Data From Checkmate 153  David Waterhouse, Leora Horn, Craig."— Presentation transcript:

1 P2.33: Safety Profile of Nivolumab Administered as 30-Minute (MIN) Infusion: Analysis of Data From Checkmate 153  David Waterhouse, Leora Horn, Craig Reynolds, David Spigel, Jason Chandler, Tarek Mekhail, Mohamed Mohamed, Ben Creelan, Kenneth B. Blankstein, Petros Nikolinakos, Michael J. Mccleod, Ang Li, Ian M. Waxman, Nivedita Aanur, Shruti Agrawal, Eduardo Richardet  Journal of Thoracic Oncology  Volume 11, Issue 10, (October 2016) DOI: /j.jtho Copyright © Terms and Conditions

2 Journal of Thoracic Oncology 2016 11, DOI: (10. 1016/j. jtho. 2016. 08
Copyright © Terms and Conditions

Download ppt "P2.33: Safety Profile of Nivolumab Administered as 30-Minute (MIN) Infusion: Analysis of Data From Checkmate 153  David Waterhouse, Leora Horn, Craig."

Similar presentations

SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
Journal of Thoracic Oncology  Volume 11, Issue 4, Pages (April 2016)

Journal of Thoracic Oncology  Volume 11, Issue 4, Pages (April 2016)
MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial 

MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial 
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Journal of Thoracic Oncology  Volume 12, Issue 3, Pages (March 2017)

Journal of Thoracic Oncology  Volume 12, Issue 3, Pages (March 2017)
MA12.09 Comparative Histological Subtype Analysis of Lung Adenocarcinoma Tumor and Metastatic Lymph Nodes and the Prognostic Impact  Shaohua Lu, Takashi.

MA12.09 Comparative Histological Subtype Analysis of Lung Adenocarcinoma Tumor and Metastatic Lymph Nodes and the Prognostic Impact  Shaohua Lu, Takashi.
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
P2.01-082 Transcriptional Profiling Identified the Anti-Proliferative Effect of Mitofusin-2 Deficiency and Its Risk in Lung Adenocarcinoma  Yuqing Lou,

P Transcriptional Profiling Identified the Anti-Proliferative Effect of Mitofusin-2 Deficiency and Its Risk in Lung Adenocarcinoma  Yuqing Lou,
OA20.03 Tumoral IL-7 Receptor is a Potential Target for Lung Adenocarcinoma Immunotherapy  Ming-Ching Lee, Takashi Eguchi, Zachary Tano, Kyuichi Kadota,

OA20.03 Tumoral IL-7 Receptor is a Potential Target for Lung Adenocarcinoma Immunotherapy  Ming-Ching Lee, Takashi Eguchi, Zachary Tano, Kyuichi Kadota,
P1.07-038 Typical Morphological Features Revealed Unfavorable Survival Benefits in High-Grade Neuroendocrine Carcinomas  Hao-Ran Zhai, Jia-Tao Zhang,

P Typical Morphological Features Revealed Unfavorable Survival Benefits in High-Grade Neuroendocrine Carcinomas  Hao-Ran Zhai, Jia-Tao Zhang,
P2.04-054 Pleural CEA and C-Reactive Protein in Patients with Lung Metastases and Malignant Pleural Effusion. A Prospective Case-Control Study  Franco.

P Pleural CEA and C-Reactive Protein in Patients with Lung Metastases and Malignant Pleural Effusion. A Prospective Case-Control Study  Franco.
Journal of Thoracic Oncology  Volume 12, Issue 4, Pages (April 2017)

Journal of Thoracic Oncology  Volume 12, Issue 4, Pages (April 2017)
Journal of Thoracic Oncology  Volume 12, Issue 5, Pages (May 2017)

Journal of Thoracic Oncology  Volume 12, Issue 5, Pages (May 2017)
OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC)  Taofeek Owonikoko,

OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC)  Taofeek Owonikoko,
Journal of Thoracic Oncology  Volume 13, Issue 2, Pages (February 2018)

Journal of Thoracic Oncology  Volume 13, Issue 2, Pages (February 2018)
P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153  David Spigel,

P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153  David Spigel,
PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC 

PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC 
In This Issue Journal of Thoracic Oncology

In This Issue Journal of Thoracic Oncology
Journal of Thoracic Oncology  Volume 11, Issue 2, Pages (February 2016)

Journal of Thoracic Oncology  Volume 11, Issue 2, Pages (February 2016)

Similar presentations

Ads by Google